Truxima™ (CT-P10) is the first biosimilar rituximab medication approved by European Medicines Agency(EMA) in February 2017.
Truxima™ is a biosimilar rituximab which demonstrates high comparability to the reference medicinal product. Truxima™ reduces disease symptoms by specifically inhibiting the overactive growth and excessive spread of B cells. Truxima™ is used for
the patients with the treatment of (lymphoma, leukemia and autoimmune disorders.) non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis(GPA), and microscopic polyangiitis(MPA).
Truxima ™,the world first biosimilar rituximab (approved in 2017 by EMA)
- Indications : Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
- Protein type : Monoclonal antibody (mAb)
- Mechanism of action : Targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis.
This product information is to provide medical information and educational purpose only. Not intended for the promotion or sales of the product. Ask your doctors or healthcare professionals for the detailed information.